Moderna Soared 8% on Cancer Data. Friday’s Report Shows Whether It Can Afford the Pipeline
Moderna's stock rose 13% on Wednesday to a 52-week high after positive early data for its multiple myeloma therapy and Ebola vaccine recommendation, then fell 5% on Thursday. Pfizer and BioNTech reported declines in COVID-19 vaccine sales, which could impact Moderna's revenue. Moderna reports Q3 results on Friday, with analysts expecting around $860 million in revenue, down from last year's $1 billion. The company's stock trades near its highest forward sales multiple in five years.
How this was made
The 30-second read
Why it matters
The trial read‑out provides a fresh catalyst that could shift short‑term price dynamics.
Market read
Moderna's stock reacts sharply to early trial data, offering a near‑term trading opportunity.
What to watch
Moderna's cash burn constraints and reliance on vaccine revenue could limit long‑term upside despite the data.
Background
Moderna recently cut costs and aims to fund its cancer pipeline while its COVID vaccine revenue declines.
Ticker impact
Moderna's early Phase 1/2 data for mRNA-2808 showed four confirmed responses among 11 evaluable patients, sparking a 13% stock jump.
upward pressure as the market prices in the encouraging efficacy signals.
The data represent the first public read‑out of the multiple myeloma therapy; such news typically drives short‑term buying.
Market effects
Early success may boost the broader mRNA oncology pipeline and lift peer biotech stocks.
U.S. biotech sector gains modestly as investors reassess cancer‑therapy pipelines.
Limited to biotech investors; no immediate macro impact.
Counterpoint
The data are early‑stage and from a small patient set; efficacy may not translate to later trials, so caution is warranted.
Key entities
- companyModerna
Biotech firm developing mRNA‑based cancer therapies.
- companyMerck
Co‑developer of the intismeran cancer therapy with Moderna.
